Consonance Capital Management LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Consonance Capital Management LP
CRD #162717
SEC #801-75000
CIK #0001544773
AUM
Employees 4 (75% Investors, 0% Brokers)
Fees
Minimum
Phone212-660-8060
Address1370 Avenue of The Americas
New York, NY 10019
Source [IAPD] [EDGAR] [Website]
Total AUM ($B)
3.02.41.81.20.60.02009201420192025
Fees and Compensation — Form ADV Part 2A (3/31/2022) [Brochure]
Item 5 – Fees and Compensation

The adviser receives a monthly investment management fee as described below from investors in the funds,
and Consonance Capital Advisors receives an allocation of profits. Please see Item 6 below for a discussion
of the performance-based allocation to Consonance Capital Advisors and Consonance Opportunity
Advisors.

Management Fees

With respect to Consonance Capital Master, Consonance Capital Onshore and Consonance Capital
Offshore, the management fee will range between 1.50% and 2.00% per annum. The fee varies between
Classes and is based on the net asset value of the Capital Account balance of each Limited Partner without
accrual of any Performance Allocation not yet earned, and payable monthly in advance as of the beginning
of each month. For Class A and H investors, the management fee will be equal to 2.00% per annum. For
Class B investors, who have aggregate balances of between $25 million and $100 million, the management
fee will range from 1.75% and 2.00% per annum, depending on the AUM of these funds. For Class O
investors, who have aggregate balances of $100 million or greater, the management fee will range from
1.50% to 2.00% per annum, depending on the AUM of these funds. The adviser, or its affiliate, may
negotiate (and has previously negotiated) different management fees at its discretion. If an investor
withdraws from a fund or the investment management agreement is terminated before the end of the month,
the adviser will refund a pro rata portion of the management fee.

For purposes of determining the management fee, all expenses and fees will be deemed to be incurred at
the Consonance Capital Master level. Consonance Capital Master will establish sub-accounts (“Consonance
Capital Sub-Accounts”) for each investor in the funds that permit Consonance Capital Master to properly
determine the management fee for each investor. Since the adviser will receive the management fee at the
master fund level, no additional fee will be paid at the fund level. The adviser may waive, reduce or rebate
the management fee with respect to any investor. The adviser has waived the management fee for affiliates
of the adviser and Consonance Capital Advisors. Management fees are deducted from the funds’ accounts.

With respect to Consonance Opportunity Master, Consonance Opportunity Onshore and Consonance
Opportunity Offshore, the management fee will range between 1.00% and 2.00% per annum. The fee varies
between series and is based on the net asset value of the Capital Account balance of each Limited Partner
without deduction of any Entity-Level Taxes (as defined in the fund’s memoranda) or any accrual of any
Performance Allocation not yet earned, and is payable monthly in advance as of the beginning of each
month. For Series A investors, the management fee will be equal to 1.5%. For Series B investors, the
management fee will be equal to 2.0%. For Series C investors, the management fee will be 1.0%. The
adviser, or its affiliate, may negotiate (and has previously negotiated) different management fees at its
discretion. If an investor withdraws from a fund or the investment management agreement is terminated
before the end of the month, the adviser will refund a pro rata portion of the management fee.

For purposes of determining the management fee, all expenses and fees will be deemed to be incurred at
the Consonance Opportunity Master level. Consonance Opportunity Master will establish sub-accounts
(“Consonance Opportunity Sub-Accounts”) for each investor in the funds that permit Consonance
Opportunity Master to properly determine the management fee for each investor. Since the adviser will
receive the management fee at the master fund level, no additional fee will be paid at the fund level. The
adviser may waive, reduce or rebate the management fee with respect to any investor. The adviser has
waived the management fee for affiliates of the adviser and Consonance Capital Opportunity Advisors.
Management fees are deducted from the funds’ accounts.

Management fees for the managed account are paid quarterly in arrears. The management fee is individually
negotiated between the adviser and the managed account.

The adviser will bear all of its own normal and recurring operating expenses incurred in connection with
the investment management services that it will provide to the clients.

Expenses

Each fund bears the legal, accounting and administrative expenses associated with the organization of the
fund and the ongoing offering of the interests or shares of the fund. Each fund also bears all costs and
expenses related to its investments and its operations, including, without limitation, brokerage and other
transaction costs, clearing and settlement charges, trade break fees, consulting expenses, legal fees and
other expenses in connection with conducting due diligence and negotiating the terms of certain
investments, custodial fees, initial and varying margin interest and commitment fees on debit balances or
borrowings, stock borrowing fees and proxy solicitation expenses, legal expenses, audit and tax preparation
expenses, accounting fees, fees and expenses of an administrator, insurance expenses including costs of any
liability insurance obtained on behalf of the funds, indemnification expenses, the management fee,
regulatory costs and expenses (including filing and license fees), any issue or transfer taxes chargeable in
connection with any securities transactions, any entity level withholding taxes and fees, costs of litigation
or investigation involving the fund activities, and any extraordinary expenses. The funds will also pay for
trade errors unless these errors involve willful misconduct or gross negligence on the part of the adviser in
the performance of its services.

Consonance Capital Onshore and Consonance Capital Offshore will also be responsible for their pro rata
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2022) [Brochure]
Item 7 – Types of Clients

The adviser provides investment advice to the funds, as described above in Item 4. The adviser may consider
fund clients if they have sufficient assets to carry on their potential investment program.

The funds will offer interests only to certain qualified investors who meet qualification requirements under
applicable securities laws and other laws. Admission to the funds is not open to the general public.

The funds have also set minimum requirements and minimum investment amounts for investors. The
minimum initial investment with respect to the funds is $1,000,000. The funds have accepted contributions
of a lesser amount, at the sole discretion of the adviser and/or Consonance Capital Advisors and/or
Consonance Capital Opportunity Advisors.

The adviser also provides investment advice to the managed account. It should be noted that the managed
account relationship is individually negotiated and subject to an account minimum.
Sector Form 13F Holdings Value ($M)
Consonance-HFW Acquisition Corp 7.1
Consonance-HFW Acquisition Corp 0.2
 
 
 
 
 
 
 
 
 
Holdings by Sector ($M)
19001520114076038002012201520192023
Type Form D Funds Date Sold AUM
HF Consonance Capital Opportunity Master Fund LP [2020-02-27] 82.5 M 16.9 M
Filed 2021-01-19 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Consonance Capital Co-Invest LLC Series A [2019-03-01] 1.5 M
Filed 2019-01-28 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Consonance Capital Master Account LP [2012-03-27] 708.7 M 27.5 M
Filed 2021-02-25 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Finder's Fee $2,904,291 · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 6 0.0
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 6 0.0
By Discretionary
Discretionary 6 0.0
Non-Discretionary 0 0.0
Total 6 0.0
By Non-United States Persons
Non-United States Persons 0.0
United States Persons 0.0
Total 6 0.0
Form D Directors Role # Filings # Firms 2011 - 2026
Mitchell Blutt MD Executive Officer 7 3
Mitchell Blutt Executive Officer 6 3
Benny Soffer Executive Officer 4 2
Douglas Lewis Executive Officer 3 2
Kevin Livingston Executive Officer 3 1
Reza Keshavarz Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001544773]
3 [0001544773]
4 [0001544773]
SC 13D [0001544773]
SC 13G [0001544773]
Form 13D/13G Filer Form 13D/13G Subject Filed
Consonance Capital Management LP GenMark Diagnostics Inc [2021-02-17]
Consonance Capital Management LP Protagonist Therapeutics Inc [2021-02-17]
Consonance Capital Management LP Assembly Biosciences Inc [2021-02-17]
Consonance Capital Management LP CASI Pharmaceuticals Inc [2021-02-17]
Consonance Capital Management LP Cellectar Biosciences Inc [2021-02-17]
Consonance Capital Management LP Gamida Cell Ltd [2021-02-17]
Consonance Capital Management LP Protagonist Therapeutics Inc [2021-02-16]
Consonance Capital Management LP SIO Gene Therapies Inc [2021-02-16]
Consonance Capital Management LP Assembly Biosciences Inc [2021-02-16]
Consonance Capital Management LP SIO Gene Therapies Inc [2021-02-16]
View All
Firm Profile (Form ADV)
Discretionary AUM$0.5B
ServesInstitutional
Fund TypesHedge Fund
LEI549300UFH280DE39TF17
Form 3/4/5 Subject 2011 - 2026
Soffer Benny
Livingston Kevin Harold
Consonance Capital Management LP
Consonance Capman GP LLC
Surrozen Inc/DE
Blutt Mitchell J MD
Consonance Life Sciences
Consonance Capital Opportunity Fund Management LP
Vericel Corp
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Surrozen Inc/DE SRZN
Warrants (right to buy) · derivative
2022-12-14 Sell 150,275
Surrozen Inc/DE SRZN
Warrants (right to buy) · derivative
2022-12-14 Sell 144,666
Surrozen Inc/DE SRZN
Warrants (right to buy) · derivative
2022-12-14 Sell 582,916
Surrozen Inc/DE SRZN
Warrants (right to buy) · derivative
2022-12-14 Sell 432,639
Surrozen Inc/DE SRZN
Common Stock
2022-12-14 Sell 1,748,750
Surrozen Inc/DE SRZN
Common Stock
2022-12-14 Sell 1,885,000
Surrozen Inc/DE SRZN
Common Stock
2022-12-14 Sell 450,827
Surrozen Inc/DE SRZN
Common Stock
2022-12-14 Sell 1,297,922
Surrozen Inc/DE SRZN
Common Stock
2021-08-11 Grant 500,000
Surrozen Inc/DE SRZN
Class A Ordinary Shares
2021-08-11 Disposed to issuer 500,000
Surrozen Inc/DE SRZN
Warrants (right to buy) · derivative
2021-08-11 Grant 416,250
Surrozen Inc/DE SRZN
Warrants (right to buy) · derivative
2021-08-11 Grant 308,940
Surrozen Inc/DE SRZN
Warrants (right to buy) · derivative
2021-08-11 Buy 166,667
Surrozen Inc/DE SRZN
Warrants (right to buy) · derivative
2021-08-11 Buy 123,700
Surrozen Inc/DE SRZN
Warrants (right to buy) · derivative
2021-08-11 Buy 42,966
Surrozen Inc/DE SRZN
Warrants (right to buy) · derivative
2021-08-11 Grant 107,309
Surrozen Inc/DE SRZN
Common Stock
2021-08-11 Grant 371,100
Surrozen Inc/DE SRZN
Common Stock
2021-08-11 Grant 321,928
Surrozen Inc/DE SRZN
Common Stock
2021-08-11 Grant 926,822
Surrozen Inc/DE SRZN
Common Stock
2021-08-11 Grant 1,248,750
showing 20 of 27 most recent transactions
Related Firms State AUM
Consonance Capital Partners LP
NY 2,761.9 M
Consonance Capital Management LP
NY
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com